" class="no-js "lang="en-US"> Neurovation Labs Awarded Additional Air Force Phase II Contract Worth $1.25M to Develop Tools to Mitigate PTSD and Other Brain Traumas - Medtech Alert
Tuesday, May 28, 2024

Neurovation Labs Awarded Additional Air Force Phase II Contract Worth $1.25M to Develop Tools to Mitigate PTSD and Other Brain Traumas

Neurovation Labs, Inc., a biotechnology company developing the first objective diagnostic and companion treatment for Post-traumatic Stress Disorder (PTSD), today announced that it has been awarded a second U.S. Air Force Small Business Innovation Research (SBIR) Direct to Phase II contract through AFWERX and Air Force Research Lab (AFRL). This contract follows a Phase I contract in December 2019 and a Phase II contract in June 2020, where the company gained the sponsorship of the Air Force Special Operations Command (AFSOC) 24th Special Operations Wing to continue development of the PTSD diagnostic and treatment. This Phase II contract will significantly accelerate the development of these pivotal healthcare technologies, as well as explore expansion into detecting Traumatic Brain Injury (TBI), including mild TBI (mTBI).

Two of the most significant issues affecting long-term soldier health are TBI and PTSD, which often occur together. In fact, after a trauma, over one-third of soldiers with TBI also have concurrent PTSD. Civilians are impacted as well, with 8-10% of the U.S. population suffering from PTSD, caused by accidents, assaults, natural disasters, and other traumas, and many more suffering from TBI. Meanwhile, brain trauma is closely tied to homelessness, joblessness, drug misuse, and a staggering suicide rate.

Neurovation Labs is addressing critical shortcomings in brain trauma healthcare by assessing and targeting underlying biomarkers. The company’s first two products focus on PTSD, which is currently poorly diagnosed using subjective symptom checklists and then treated by off-target, ineffective drugs or by various cognitive therapies. Neurovation Labs is targeting a localized protein increase in the brain to develop the first diagnostic brain scan and companion medication for the disorder. With this Phase II contract, the company will be extending use of its diagnostic platform to detect mTBI before outward behavioral symptoms manifest.

“We are incredibly excited to continue our work with AFWERX and the U.S. Air Force on the development of our brain trauma healthcare platform,” stated CEO Dr. Jennifer Perusini. “This partnership not only validates the need for our products but also ensures we are providing solutions that fit within both civilian and military healthcare systems. Our goal at Neurovation Labs is to revolutionize mental healthcare for everyone, with a precision molecular approach.”

Prior to this AFWERX contract, the company was a finalist in the U.S. Army xTechSearch 5 competition and participated in the xTech Accelerator powered by FedTech. In total, Neurovation Labs has received over $2.25 million in awards and contracts from the U.S. military.

People In This Post

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more